Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral pentosan polysulfate for knee osteoarthritis with hypercholesterolemia
ACTRN12621000654853Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Jul 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing Sodium pentosan polysulfate with Placebo (2 arms). Primary endpoint: Change in 24-hour pain intensity numeric rating scale. Started Jul 2023; status: completed.
02
Drugs
pentosan polysulfate sodium
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12621000654853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000654853.